SOD1 and Huntington disease: Significantly, clinical trials have been conducted in patients (Miller et al., 2013; Tabrizi et al., 2019) using ASOs targeting superoxide dismutase 1 (SOD1) in ALS and the mutant huntingtin gene in Huntington’s disease.